Research programme: anticancer therapeutics - LigaChem Biosciences/Newgex
Alternative Names: I HSP90 (1) - LigaChem Biosciences; I HSP90 (2) - LigaChem BiosciencesLatest Information Update: 08 Jan 2025
At a glance
- Originator LegoChem Biosciences; Newgex
- Developer LigaChem Biosciences
- Class
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in South Korea